Showing 531-540 of 1697 results for "".
The FDA File
https://practicalneurology.com/columns/practice-management/the-fda-file/30324/Pain and Gain: Reassessing Hydrocodone Prescribing
https://practicalneurology.com/diseases-diagnoses/headache-pain/pain-and-gain-reassessing-hydrocodone-prescribing/30742/New recommendations by an FDA committee aim to decrease opioid abuse, the group says, but will physicians and patients bear the burden of its effects?Rising Drug Prices and the Cost of Care: What Can Physicians Do?
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/rising-drug-prices-and-the-cost-of-care-what-can-physicians-do/30327/The multiple sclerosis drug market offers a snapshot of a growing problem. Physicians should speak out on behalf of the specialty and their patients.Pay Attention: Neurology and ADHD, Part 1
https://practicalneurology.com/diseases-diagnoses/child-neurology/pay-attention-neurology-and-adhd-part-1/30573/What do neurologists need to know about ADHD? A specialist gives an overview on childhood presentations. Next month: A look at adult patients.Maintaining Ambulation
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/maintaining-ambulation/30126/Physical therapy, exercise, physical activity, and medications adapted to individual needs can all help maintain the ability to walk.Pediatric-Onset Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/pediatric-onset-multiple-sclerosis/30128/Information from clinical trials in children with MS is furthering understanding and improving treatment options for this rare presentation.The Digital Future of Cognitive Screening
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/the-digital-future-of-cognitive-screening/30395/As continued research elucidates Alzheimer's disease biomarkers, cognitive screening tools will play an integral role in the early detection of impairment.Neurotoxin Therapy: A Closer Look at the Four Options
https://practicalneurology.com/columns/practice-management/neurotoxin-therapy-a-closer-look-at-the-four-options/30818/The field of neurotoxins has grown recently, but how do the agents compare? Here's a closer look at the therapies available on the US market.- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31497/Natalizumab (Tysabri) in Multiple Sclerosis Management: A Comprehensive OverviewNatalizumab, marketed as Tysabri, represents a significant advancement in the treatment of relapsing-remitting multiple sclerosis (RRMS). As the first α4-integrin antagonist within the selective adhesion molecule (SAM) i
Headache Horizons: Tuning in to Psychedelics for Treatment of Suicide Headaches
https://practicalneurology.com/diseases-diagnoses/headache-pain/headache-horizons-tuning-in-to-psychedelics-for-treatment-of-suicide-headaches/30174/Neurologists need to understand the phenomenon of using psychedelic drugs for cluster-busting and advocate for appropriate research.